TESARO (TSRO) to Offer $300M in Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
TESARO Announces Proposed Public Offering of Common Stock
June 30, 2016 6:38 AM EDTWALTHAM, Mass., June 30, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO) announced today that it has commenced an underwritten public offering of $300 million of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional $45 million of its common stock. Citigroup, Leerink Partners, Credit Suisse and Wells Fargo Securities are acting as bookrunners, and Mizuho, Raymond James, SunTrust Robinson Humphrey and Wedbush PacGrow are acting as co-managers for the offering. The offering is subject to market conditions, and there... More
TESARO’s Niraparib Significantly Improved Progression-Free Survival for Patients With Ovarian Cancer in Both Cohorts of the Phase 3 NOVA Trial
June 29, 2016 7:00 AM EDTThe NOVA trial successfully achieved its primary endpoint of PFS in the germline BRCA mutant cohort  The NOVA trial successfully achieved its primary endpoint of PFS in the non-germline BRCA mutant cohort, including both the HRD-positive and overall analysis populationsNOVA is the first successful prospectively designed Phase 3 trial of a PARP inhibitorNDA and MAA submissions are planned for Q4 2016
WALTHAM, Mass., June 29, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that the Phase... More
